Julie Brahmer named director of thoracic oncology at Johns Hopkins Kimmel Cancer Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

JULIE BRAHMER was named director of the Thoracic Oncology Program at the Johns Hopkins Kimmel Cancer Center.

Brahmer will oversee a $35 million investment in the program and the opening of the new Thoracic Center of Excellence at Johns Hopkins Bayview Medical Center, as well as clinical trials and research focused on lung and esophageal cancer and mesothelioma.

Brahmer has been a faculty member at Johns Hopkins since 2001. She is a member of the American Society of Clinical Oncology and the Eastern Cooperative Oncology Group’s Thoracic Committee and Cancer Prevention Steering Committee. A founding board member of the National Lung Cancer Partnership, now known as Free to Breathe, she currently serves as a member of its Scientific Executive Committee.

She also sits on the Lung Cancer Research Foundation’s Medical Advisory Board, Uniting Against Lung Cancer’s Medical Committee and LUNGevity’s Scientific Advisory Board.

YOU MAY BE INTERESTED IN

At the Sept. 4 meeting of the National Cancer Advisory Board, NCI Principal Deputy Director Douglas R. Lowy provided an overview of how NCI is weathering the maelstrom of executive orders, policy changes, and funding uncertainties that has come down on federal agencies and research institutes since Donald Trump’s inauguration in January. 
A Senate hearing that the administration hoped would be a routine check-in on the president’s 2026 MAHA-driven healthcare agenda erupted into a political firestorm as senators jumped at their first opportunity to confront HHS Secretary Robert F. Kennedy Jr. over the chaos engulfing the Centers for Disease Control and Prevention.
In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login